公开(公告)号：SG10201809111XA

公开(公告)日：2018-11-29

申请号：SG10201809111X

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

Abstract: THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. Fig. 1

公开(公告)号：NZ772688A

公开(公告)日：2022-09-30

申请号：NZ77268811

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Use of ibrutinib as an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), in the manufacture of a medicament for treating chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), wherein said medicament is to be administered in an oral dose of 420 mg of said inhibitor once per day until progression of the CLL or SLL or unacceptable toxicity; and lymphocytosis is not considered progression of the CLL or SLL.

公开(公告)号：NZ755485A

公开(公告)日：2021-04-30

申请号：NZ75548511

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK ,  FYFE GWEN ,  BUGGY JOSEPH

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Use of ibrutinib in the manufacture of a medicament for treating multiple myeloma (MM) in an individual in need thereof, wherein the medicament is formulated for administration at an ibrutinib dosage of about 420 to about 840 mg once per day in a solid oral dosage form. Preferably the medicament is in the form of capsules containing a once per day dosage of 420 mg, 560 mg or 840 mg.

公开(公告)号：AU2013245503B2

公开(公告)日：2015-09-24

申请号：AU2013245503

申请日：2013-10-17

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  VERNER ERIK ,  CHEN WEI ,  HONIGBERG LEE ,  BUGGY JOSEPH

IPC: A61K31/52 ,  A61P35/00

Abstract: Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

公开(公告)号：AU2009270856B2

公开(公告)日：2013-07-25

申请号：AU2009270856

申请日：2009-07-16

Applicant: PHARMACYCLICS LLC

Inventor： CHEN WEI ,  VERNER ERIK ,  LOURY DAVID ,  BUGGY JOSEPH ,  HONIGBERG LEE

IPC: A61K31/52 ,  A61P35/00

Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

公开(公告)号：NZ736048A

公开(公告)日：2019-09-27

申请号：NZ73604811

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： LOURY DAVID ,  HEDRICK ERIC ,  ELIAS LAURENCE ,  MODY TARAK ,  FYFE GWEN ,  BUGGY JOSEPH

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Described is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) in the manufacture of a medicament for treating relapsed or refractory follicular lymphoma in an individual in need thereof, wherein the medicament is formulated for administration of the compound once per day in an amount of about 560 mg, in a solid oral dosage form.

公开(公告)号：CA3113343A1

公开(公告)日：2011-12-08

申请号：CA3113343

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：NZ753024A

公开(公告)日：2020-08-28

申请号：NZ75302411

申请日：2011-06-03

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID ,  MODY TARAK

IPC: A61K31/519 ,  A61K31/4162 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

Abstract: Disclosed is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) in the manufacture of a medicament for treating diffuse large B-cell lymphoma (DLBCL) in an individual in need thereof, wherein the medicament is formulated for administration of the compound once per day in an amount of about 560 mg, in a solid oral dosage form.

公开(公告)号：HK1254663A1

公开(公告)日：2019-07-26

申请号：HK18113642

申请日：2018-10-24

Applicant: PHARMACYCLICS LLC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH ,  LOURY DAVID ,  CHEN WEI

IPC: A61K20060101 ,  A61P20060101

公开(公告)号：ES2660418T3

公开(公告)日：2018-03-22

申请号：ES09798770

申请日：2009-07-16

Applicant: PHARMACYCLICS LLC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH ,  LOURY DAVID ,  CHEN WEI

IPC: A61K31/52 ,  A61K31/00 ,  A61K31/519 ,  A61P35/00

Abstract: Composición farmacéutica para usar en el tratamiento de cáncer de mama seleccionado de carcinoma ductal mamario y carcinoma lobular que comprende el compuesto de la fórmula: **Fórmula** o una sal farmacéuticamente aceptable del mismo y uno o más portadores fisiológicamente aceptables.